


## PHARMACEUTICAL 2022

## POINT Biopharma Global Inc. Rank 28 of 466





## PHARMACEUTICAL 2022



## POINT Biopharma Global Inc. Rank 28 of 466

The relative strengths and weaknesses of POINT Biopharma Global Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of POINT Biopharma Global Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 48% points. The greatest weakness of POINT Biopharma Global Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 290%, being 212% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	243,847
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,980
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	306
Other Liabilities	66
Other Net Income	-85
Other Revenues	0
Property and Equipment	19,412
Research and Development	33,505
Selling, General and Administrative Expense	12,006

Output Variable	Value in 1000 USD
Assets	263,259
Liabilities	8,046
Expenses	45,817
Revenues	0
Stockholders Equity	255,213
Net Income	-45,902
Comprehensive Net Income	-45,902
Economic Capital Ratio	290%

